Drugs / CB-03-10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03863145 | Jun 2022 → Jan 2026 | refractory malignant neoplasm | Cosmo Technologies Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-03-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03863145 ↗ |
| Route | Oral | “for oral use” NCT03863145 ↗ |